Combination therapies with curaxins
Provided herein are methods and compositions that relate to, inter alia, CBL0137, a carbazole compound 1,1′-[9-[2-[(1-methylethyl)amino]ethyl]-9H-carbazole-3,6-diyl]bis-ethanone, useful for the treatment of various cancers, optionally in combination with various agents.
1. A method for treating hepatocellular carcinoma, comprising administering an effective amount of CBL0137 and a kinase inhibitor chemotherapeutic agent to a subject in need thereof, wherein the kinase inhibitor chemotherapeutic agent is sorafenib.
2. The method of claim 1 , wherein the CBL0137 is administered after administration of sorafenib.
3. The method of claim 1 , wherein the CBL0137 is co-administered with sorafenib.
4. The method of claim 1 , wherein the CBL0137 and/or sorafenib is administered intravenously and/or orally.
5. The method of claim 1 , wherein the CBL0137 and/or sorafenib is administered at a sub-therapeutic dose.
6. The method of claim 1 , wherein the therapeutic window of CBL0137 and/or sorafenib is increased.
7. The method of claim 1 , wherein the subject is undergoing treatment with sorafenib.
8. A method for treating pancreatic ductal adenocarcinoma or non-small cell lung cancer, comprising administering an effective amount of CBL0137 and a nucleoside analog chemotherapeutic agent to a subject in need thereof, wherein the nucleoside analog chemotherapeutic agent is gemcitabine.
9. The method of claim 8 , wherein the CBL0137 is administered after administration of gemcitabine.
10. The method of claim 8 , wherein the CBL0137 is co-administered with gemcitabine.
11. The method of claim 8 , wherein the CBL0137 and/or gemcitabine is administered intravenously and/or orally.
12. The method of claim 8 , wherein the CBL0137 and/or gemcitabine is administered at a sub-therapeutic dose.
13. The method of claim 8 , wherein the therapeutic window of CBL0137 gemcitabine is increased.
14. The method of claim 8 , wherein the subject is undergoing treatment with gemcitabine.